That was as of 12/31/17. Shares as of 3/31/18 were 595 million and 412 million, respectively. Either way it's no shot at POT!\!, its just saying RXMD is severely undervalued. Debt doesn't even compare, and still way less outstanding shares.
"To Give Anything Less Than Your Best, Is To Sacrifice the Gift." - Steve Prefontaine